JP6130097B2 - ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体 - Google Patents

ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体 Download PDF

Info

Publication number
JP6130097B2
JP6130097B2 JP2011529562A JP2011529562A JP6130097B2 JP 6130097 B2 JP6130097 B2 JP 6130097B2 JP 2011529562 A JP2011529562 A JP 2011529562A JP 2011529562 A JP2011529562 A JP 2011529562A JP 6130097 B2 JP6130097 B2 JP 6130097B2
Authority
JP
Japan
Prior art keywords
seq
nos
cdrhs
cdrls
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011529562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504402A (ja
JP2012504402A5 (show.php
Inventor
クファー，ペーター
ラウム，トビアス
キッシェル，ロマン
ルッターブゼ，ラルフ
ホフマン，パトリック
ラウ，ドリス
クリンガー，マシュアス
マンゴールド，スザンネ
ブリュメル，クラウディア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6130097(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micromet GmbH, Amgen Research Munich GmbH filed Critical Micromet GmbH
Publication of JP2012504402A publication Critical patent/JP2012504402A/ja
Publication of JP2012504402A5 publication Critical patent/JP2012504402A5/ja
Application granted granted Critical
Publication of JP6130097B2 publication Critical patent/JP6130097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011529562A 2008-10-01 2009-10-01 ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体 Active JP6130097B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US10193308P 2008-10-01 2008-10-01
US10184408P 2008-10-01 2008-10-01
US10185008P 2008-10-01 2008-10-01
US10184608P 2008-10-01 2008-10-01
US10192108P 2008-10-01 2008-10-01
US10185308P 2008-10-01 2008-10-01
US10192708P 2008-10-01 2008-10-01
US61/101,846 2008-10-01
US61/101,933 2008-10-01
US61/101,853 2008-10-01
US61/101,850 2008-10-01
US61/101,927 2008-10-01
US61/101,844 2008-10-01
US61/101,921 2008-10-01
PCT/EP2009/062792 WO2010037835A2 (en) 2008-10-01 2009-10-01 Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134816A Division JP6254552B2 (ja) 2008-10-01 2015-07-03 ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体

Publications (3)

Publication Number Publication Date
JP2012504402A JP2012504402A (ja) 2012-02-23
JP2012504402A5 JP2012504402A5 (show.php) 2013-03-21
JP6130097B2 true JP6130097B2 (ja) 2017-05-17

Family

ID=42073955

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011529562A Active JP6130097B2 (ja) 2008-10-01 2009-10-01 ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体
JP2015134816A Active JP6254552B2 (ja) 2008-10-01 2015-07-03 ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体
JP2017222266A Pending JP2018064565A (ja) 2008-10-01 2017-09-15 ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015134816A Active JP6254552B2 (ja) 2008-10-01 2015-07-03 ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体
JP2017222266A Pending JP2018064565A (ja) 2008-10-01 2017-09-15 ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体

Country Status (16)

Country Link
US (2) US20120034228A1 (show.php)
EP (1) EP2370467B1 (show.php)
JP (3) JP6130097B2 (show.php)
KR (2) KR101942694B1 (show.php)
CN (1) CN102164961B (show.php)
AU (1) AU2009299791B2 (show.php)
BR (1) BRPI0919840B1 (show.php)
CA (1) CA2738545A1 (show.php)
ES (1) ES2604309T3 (show.php)
IL (1) IL212100A (show.php)
MX (1) MX338038B (show.php)
NZ (1) NZ591087A (show.php)
RU (1) RU2547600C2 (show.php)
SG (1) SG194399A1 (show.php)
WO (1) WO2010037835A2 (show.php)
ZA (1) ZA201101066B (show.php)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
NZ591087A (en) * 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US10981998B2 (en) * 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
SG10201501767VA (en) 2010-03-10 2015-05-28 Genmab As Monoclonal antibodies against c-met
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
US8603478B2 (en) 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
KR102447595B1 (ko) 2010-11-30 2022-09-26 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
CA2820782A1 (en) * 2010-12-10 2012-06-14 Merck Patent Gmbh Bispecific aptamers mediating tumour cell lysis
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
AR089114A1 (es) 2011-12-09 2014-07-30 Amgen Res Munich Gmbh PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
US9353153B2 (en) 2012-02-09 2016-05-31 Riken Cyclic RNA and protein production method
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA2898100C (en) * 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014138306A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Engager cells for immunotherapy
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CN103275225A (zh) * 2013-05-10 2013-09-04 洪建� 高亲合力抗cd31/cd146双特异单克隆抗体及其应用
WO2015057545A2 (en) 2013-10-14 2015-04-23 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
MX379210B (es) 2014-02-07 2025-03-10 Univ Mcmaster Acoplador trifuncional de antígeno de células t y métodos y usos del mismo.
EA201691925A1 (ru) 2014-03-28 2017-06-30 Ксенкор, Инк. Биспецифические антитела, которые связываются с cd38 и cd3
WO2015156268A1 (ja) 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
CA2947157A1 (en) * 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
WO2015172341A1 (zh) * 2014-05-14 2015-11-19 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
CA2895659A1 (en) 2014-07-01 2016-01-01 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US11661462B2 (en) 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
KR101615619B1 (ko) * 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
ES2850325T3 (es) 2014-10-09 2021-08-27 Engmab Sarl Anticuerpos biespecíficos contra CD3epsilon y ROR1
US20170306044A1 (en) * 2014-10-09 2017-10-26 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
SI3223605T1 (sl) * 2014-11-24 2021-03-31 Regeneron Pharmaceuticals, Inc. Nehumane živali, ki izražajo humaniziran CD3 kompleks
SG11201704274QA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
KR20240116967A (ko) 2014-11-26 2024-07-30 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
HK1254967A1 (zh) * 2015-10-02 2019-08-02 豪夫迈‧罗氏有限公司 结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
US10858423B2 (en) 2015-10-26 2020-12-08 Pierre Fabre Medicament Composition for the treatment of IGF-1R expressing cancer
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CN106810610A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
TW201720458A (zh) * 2015-12-04 2017-06-16 宏觀基因股份有限公司 能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
JP7064437B2 (ja) 2015-12-17 2022-05-10 サイオクサス セラピューティクス リミテッド 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
HUE068801T2 (hu) 2016-06-14 2025-01-28 Xencor Inc Bispecifikus kontrollpont-gátló antitestek
KR20230129583A (ko) 2016-06-21 2023-09-08 테네오바이오, 인코포레이티드 Cd3 결합 항체
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
MX2018015414A (es) * 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL264902B2 (en) * 2016-08-29 2023-11-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
HRP20240767T1 (hr) 2016-09-14 2024-09-13 Teneoone, Inc. Cd3 vezujuća antitijela
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
KR102562519B1 (ko) 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102633423B1 (ko) 2016-12-21 2024-02-06 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3634998B8 (en) 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
CA3067584A1 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
CA3065328C (en) 2017-06-21 2023-08-15 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
ES2973864T3 (es) * 2017-08-10 2024-06-24 Grifols Diagnostic Solutions Inc Composiciones, métodos y/o kits que comprenden un dominio extracelular de CD38 recombinante humano
EP3694997A4 (en) 2017-10-12 2021-06-30 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
DE102017125150B4 (de) * 2017-10-26 2019-10-10 Epiontis Gmbh Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
US12162920B2 (en) * 2018-01-26 2024-12-10 Chongqing Precision Biotech Company Limited Hinge area and use of same in constructing car skeleton
CA3096052A1 (en) * 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
MX2020012495A (es) 2018-06-01 2021-02-15 Novartis Ag Moleculas de union contra bcma y usos de las mismas.
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
MX2021006389A (es) * 2018-12-07 2021-07-15 Jiangsu Hengrui Medicine Co Anticuerpo cd3 y uso farmaceutico del mismo.
MX2021010390A (es) 2019-03-01 2021-11-17 Xencor Inc Anticuerpos heterodimericos que se unen a enpp3 y cd3.
JOP20210253A1 (ar) 2019-04-05 2023-01-30 Teneobio Inc أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ psma
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
AR119746A1 (es) 2019-06-14 2022-01-05 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
US11766453B2 (en) 2019-09-11 2023-09-26 The Trustees Of The University Of Pennsylvania Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs)
KR20220131221A (ko) 2019-11-13 2022-09-27 아뮤닉스 파마슈티컬스, 인크. 바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법
EP4045541A4 (en) * 2019-12-20 2023-08-16 Shandong Boan Biotechnology Co., Ltd. Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy
WO2021155380A1 (en) * 2020-01-31 2021-08-05 Gensun Biopharma Inc. Bispecific t cell engagers
US20230075244A1 (en) * 2020-02-20 2023-03-09 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
AU2021263448A1 (en) 2020-04-29 2022-11-24 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
JP2023529557A (ja) 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｅｎｐｐ１抗体の阻害
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4153634A4 (en) * 2020-05-19 2024-05-29 City of Hope GENETICALLY MODIFIED ANTI-PROSTATIC STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF
IL298815A (en) 2020-06-25 2023-02-01 Amunix Pharmaceuticals Inc Bispecific compositions targeting HER-2 and methods for their preparation and use
CN115698072B (zh) 2020-07-01 2023-07-04 山东博安生物技术股份有限公司 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
CN112063608B (zh) * 2020-08-27 2022-06-17 浙江工业大学 一种脂肪酸光脱羧酶突变体及其在l-草铵膦合成中的应用
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
WO2022256449A1 (en) 2021-06-01 2022-12-08 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
EP4435006A1 (en) * 2021-11-19 2024-09-25 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody and use thereof
US20240165213A1 (en) * 2022-11-21 2024-05-23 Avstera Therapeutics Corp. mRNA COMPOSITION FOR PREVENTING AND TREATING CANCER
WO2024168279A2 (en) 2023-02-10 2024-08-15 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
WO2024220397A1 (en) 2023-04-17 2024-10-24 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用
TW202534086A (zh) * 2024-02-28 2025-09-01 香港商Ｆｂｄ生物製劑有限公司 抗ｐｓｃａ抗體及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1071752T1 (en) * 1998-04-21 2003-12-31 Micromet Ag CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1629011B1 (en) 2003-05-31 2010-01-13 Micromet AG Human anti-human cd3 binding molecules
CN100509850C (zh) * 2003-05-31 2009-07-08 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
JP5010281B2 (ja) * 2003-05-31 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
BRPI0415457A (pt) * 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2555503C (en) * 2004-02-16 2018-03-27 Micromet Ag Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
SG155883A1 (en) * 2004-06-03 2009-10-29 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
MX2007000387A (es) * 2004-07-16 2007-03-28 Micromet Ag Polipeptidos de expresion mejorada.
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
NO20064183L (no) * 2005-02-16 2006-11-08 Micromet Ag Mindre immunogene bindingsmolekyler
KR20080000613A (ko) * 2005-03-25 2008-01-02 제넨테크, 인크. 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
BRPI0615745A2 (pt) * 2005-09-12 2011-05-24 Novimmune Sa formulação de anticorpo anti-cd3
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
HUE040467T2 (hu) * 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Keresztfaj-specifikus kötõdomén
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
EP2155783B2 (en) * 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Cross-species-specific cd3-epsilon binding domain
EP2257293A2 (en) * 2008-03-06 2010-12-08 Genentech, Inc. Combination therapy with c-met and egfr antagonists
US10981998B2 (en) * 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
NZ591087A (en) * 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9505849B2 (en) * 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
UY36245A (es) * 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
PL3283524T3 (pl) * 2015-04-17 2023-06-12 Amgen Research (Munich) Gmbh Konstrukty biswoistego przeciwciała dla cdh3 i cd3
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TW202346349A (zh) * 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體

Also Published As

Publication number Publication date
MX2011003501A (es) 2011-09-01
CN102164961B (zh) 2014-04-16
KR20180026581A (ko) 2018-03-12
JP2018064565A (ja) 2018-04-26
KR101837053B1 (ko) 2018-03-12
US20200362039A1 (en) 2020-11-19
CN102164961A (zh) 2011-08-24
NZ591087A (en) 2012-08-31
RU2547600C2 (ru) 2015-04-10
EP2370467A2 (en) 2011-10-05
KR20110066960A (ko) 2011-06-17
IL212100A (en) 2016-02-29
IL212100A0 (en) 2011-06-30
CA2738545A1 (en) 2010-04-08
US20120034228A1 (en) 2012-02-09
EP2370467B1 (en) 2016-09-07
BRPI0919840B1 (pt) 2023-02-28
JP2012504402A (ja) 2012-02-23
JP2016007217A (ja) 2016-01-18
KR101942694B1 (ko) 2019-01-25
ES2604309T3 (es) 2017-03-06
MX338038B (es) 2016-03-30
SG194399A1 (en) 2013-11-29
RU2011108681A (ru) 2012-11-10
WO2010037835A2 (en) 2010-04-08
WO2010037835A3 (en) 2010-07-15
ZA201101066B (en) 2012-06-27
BRPI0919840A2 (pt) 2014-09-23
AU2009299791B2 (en) 2016-02-25
AU2009299791A1 (en) 2010-04-08
JP6254552B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
JP6254552B2 (ja) ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体
JP7273106B2 (ja) 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2018064565A6 (ja) ＰＳＣＡ×ＣＤ３、ＣＤ１９×ＣＤ３、Ｃ−ＭＥＴ×ＣＤ３、エンドシアリン×ＣＤ３、ＥｐＣＡＭ×ＣＤ３、ＩＧＦ−１Ｒ×ＣＤ３、またはＦＡＰアルファ×ＣＤ３の異種間特異的二重特異性単鎖抗体
CA2738568C (en) Cross-species-specific single domain bispecific single chain antibody
JP6026986B2 (ja) 種間特異的結合ドメイン
RS53008B2 (sr) Interspecijski specifičan cd3-epsilon vezujući domen
TWI629357B (zh) 跨物種特異性的ＰＳＭＡｘＣＤ３雙特異性單鏈抗體
HK1158670B (en) Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20120921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150706

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150731

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170413

R150 Certificate of patent or registration of utility model

Ref document number: 6130097

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250